Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Alzamend Neuro, Inc. (ALZN) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to...
08/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/11/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/10/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
08/02/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/27/2023 10-K Annual Report for the period ended April 30, 2023
04/26/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’ s Type ATLANTA, GA, April 3, 2023 -- Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease , bipolar disorder, major depressive disorder and post-traumatic stress disorder , today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine to treat mild to moderate dementia of the Alzheimer’ s type. The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30 subjects with mild to moderate morbidity. The primary goal of this clini..."
03/31/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/22/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Topline data expected in June 2023"
03/16/2023 8-K Quarterly results
Docs: "Alzamend Neuro, Inc. Condensed Balance Sheets January 31, 2023 April 30, 2022 ASSETS CURRENT ASSETS Cash $ 7,375,841 $ 14,063,811 Prepaid expenses and other current assets 546,303 349,723 Prepaid expenses - related party 494,668 - TOTAL CURRENT ASSETS 8,416,812 14,413,534 Property, plant and equipment, net 85,166 102,909 TOTAL ASSETS $ 8,501,978 $ 14,516,443 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 2,642,473 $ 1,162,850 Related party payable - 2,082 TOTAL CURRENT LIABILITIES 2,642,473 1,164,932 TOTAL LIABILITIES 2,642,473 1,164,932 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001stated value per share, 1,360..."
03/15/2023 10-Q Quarterly Report for the period ended January 31, 2023
02/03/2023 8-K Quarterly results
01/20/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
12/12/2022 10-Q Quarterly Report for the period ended October 31, 2022
11/16/2022 8-K Quarterly results
11/15/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’ s Type ATLANTA, GA, October 31, 2022 -- Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease , bipolar disorder, major depressive disorder and post-traumatic stress disorder , today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration for a phase I/IIA clinical trial under its Investigational New Drug application for an immunotherapy to treat mild to moderate dementia of the Alzheimer’ s type. “We are grateful to receive this timely, favorable respons..."
10/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "About Alzamend Neuro Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s, bipolar disorder, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate, and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’ s immunological system to combat Alzheimer’ s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-be..."
09/29/2022 8-K Quarterly results
09/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement"
09/13/2022 10-Q Quarterly Report for the period ended July 31, 2022
08/15/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
07/19/2022 10-K Annual Report for the period ended April 30, 2022
07/18/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
04/28/2022 SC 13D/A AULT MILTON C III reports a 43.2% stake in Alzamend Neuro, Inc.
04/20/2022 8-K/A Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
04/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy